Mesenchymal Stem Cells: Key Players in Cancer Progression

Overview

Journal Mol Cancer

Publisher Biomed Central

Specialties Molecular Biology
Oncology

Date 2017 Feb 3

PMID 28148268

Citations 277

Authors

Sarah M Ridge

Francis J Sullivan

Sharon A Glynn

Affiliations

Soon will be listed here.

Abstract

Tumour progression is dependent on the interaction between tumour cells and cells of the surrounding microenvironment. The tumour is a dynamic milieu consisting of various cell types such as endothelial cells, fibroblasts, cells of the immune system and mesenchymal stem cells (MSCs). MSCs are multipotent stromal cells that are known to reside in various areas such as the bone marrow, fat and dental pulp. MSCs have been found to migrate towards inflammatory sites and studies have shown that they also migrate towards and incorporate into the tumour. The key question is how they interact there. MSCs may interact with tumour cells through paracrine signalling. On the other hand, MSCs have the capacity to differentiate to various cell types such as osteocytes, chondrocytes and adipocytes and it is possible that MSCs differentiate at the site of the tumour. More recently it has been shown that cross-talk between tumour cells and MSCs has been shown to increase metastatic potential and promote epithelial-to-mesenchymal transition. This review will focus on the role of MSCs in tumour development at various stages of progression from growth of the primary tumour to the establishment of distant metastasis.

Citing Articles

Contribution of tumor microenvironment (TME) to tumor apoptosis, angiogenesis, metastasis, and drug resistance.

Xiao Y, Hassani M, Moghaddam M, Fazilat A, Ojarudi M, Valilo M Med Oncol. 2025; 42(4):108.

PMID: 40087196 DOI: 10.1007/s12032-025-02675-8.

Capsanthin inhibits migration and reduces N-linked glycosylation of PD-L1 via the EZH2-PD-L1 axis in triple-negative breast cancer brain metastasis.

Chien Y, Wu J, Liu L, Yu Y Cell Death Discov. 2025; 11(1):85.

PMID: 40038276 PMC: 11880297. DOI: 10.1038/s41420-025-02368-1.

The protective effect of endurance running against the pro-invasive effects of ageing in breast cancer cells and mesenchymal stem cells .

Brown M, Nickels M, Akam E, Morris M In Vitro Model. 2025; 2(6):263-280.

PMID: 39872498 PMC: 11756502. DOI: 10.1007/s44164-023-00055-y.

Organoids and spheroids: advanced models for liver cancer research.

Pastore M, Giachi A, Spinola-Lasso E, Marra F, Raggi C Front Cell Dev Biol. 2025; 12():1536854.

PMID: 39850799 PMC: 11754960. DOI: 10.3389/fcell.2024.1536854.

Anti-Tumor Effects of Sheep Umbilical Cord Mesenchymal Stem Cells on Melanoma Cells.

Yue F, Zhao Y, Lv Y, Li S, Wang W, Li Y Int J Mol Sci. 2025; 26(1.

PMID: 39796281 PMC: 11720557. DOI: 10.3390/ijms26010426.

References

Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H . Stromal gene expression predicts clinical outcome in breast cancer. Nat Med. 2008; 14(5):518-27. DOI: 10.1038/nm1764. View

Sato Y, Araki H, Kato J, Nakamura K, Kawano Y, Kobune M . Human mesenchymal stem cells xenografted directly to rat liver are differentiated into human hepatocytes without fusion. Blood. 2005; 106(2):756-63. DOI: 10.1182/blood-2005-02-0572. View

Coleman R . Skeletal complications of malignancy. Cancer. 1997; 80(8 Suppl):1588-94. DOI: 10.1002/(sici)1097-0142(19971015)80:8+<1588::aid-cncr9>3.3.co;2-z. View

Kalluri R . The biology and function of fibroblasts in cancer. Nat Rev Cancer. 2016; 16(9):582-98. DOI: 10.1038/nrc.2016.73. View

Ramankulov A, Lein M, Kristiansen G, Loening S, Jung K . Plasma osteopontin in comparison with bone markers as indicator of bone metastasis and survival outcome in patients with prostate cancer. Prostate. 2006; 67(3):330-40. DOI: 10.1002/pros.20540. View

Ye H, Cheng J, Tang Y, Liu Z, Xu C, Liu Y . Human bone marrow-derived mesenchymal stem cells produced TGFbeta contributes to progression and metastasis of prostate cancer. Cancer Invest. 2012; 30(7):513-8. DOI: 10.3109/07357907.2012.692171. View

Ortiz L, Gambelli F, McBride C, Gaupp D, Baddoo M, Kaminski N . Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci U S A. 2003; 100(14):8407-11. PMC: 166242. DOI: 10.1073/pnas.1432929100. View

Singh S, Singh U, Grizzle W, Lillard Jr J . CXCL12-CXCR4 interactions modulate prostate cancer cell migration, metalloproteinase expression and invasion. Lab Invest. 2004; 84(12):1666-76. DOI: 10.1038/labinvest.3700181. View

Liaw L, Skinner M, Raines E, Ross R, Cheresh D, Schwartz S . The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins. Role of alpha v beta 3 in smooth muscle cell migration to osteopontin in vitro. J Clin Invest. 1995; 95(2):713-24. PMC: 295539. DOI: 10.1172/JCI117718. View

10.

Castellano G, Malaponte G, Mazzarino M, Figini M, Marchese F, Gangemi P . Activation of the osteopontin/matrix metalloproteinase-9 pathway correlates with prostate cancer progression. Clin Cancer Res. 2008; 14(22):7470-80. DOI: 10.1158/1078-0432.CCR-08-0870. View

11.

Ishijima M, Rittling S, Yamashita T, Tsuji K, Kurosawa H, Nifuji A . Enhancement of osteoclastic bone resorption and suppression of osteoblastic bone formation in response to reduced mechanical stress do not occur in the absence of osteopontin. J Exp Med. 2001; 193(3):399-404. PMC: 2195919. DOI: 10.1084/jem.193.3.399. View

12.

Waterman R, Tomchuck S, Henkle S, Betancourt A . A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype. PLoS One. 2010; 5(4):e10088. PMC: 2859930. DOI: 10.1371/journal.pone.0010088. View

13.

Brennen W, Chen S, Denmeade S, Isaacs J . Quantification of Mesenchymal Stem Cells (MSCs) at sites of human prostate cancer. Oncotarget. 2013; 4(1):106-17. PMC: 3702211. DOI: 10.18632/oncotarget.805. View

14.

Nishimori H, Ehata S, Suzuki H, Katsuno Y, Miyazono K . Prostate cancer cells and bone stromal cells mutually interact with each other through bone morphogenetic protein-mediated signals. J Biol Chem. 2012; 287(24):20037-46. PMC: 3370187. DOI: 10.1074/jbc.M112.353094. View

15.

Paunescu V, Bojin F, Tatu C, Gavriliuc O, Rosca A, Gruia A . Tumour-associated fibroblasts and mesenchymal stem cells: more similarities than differences. J Cell Mol Med. 2010; 15(3):635-46. PMC: 3922385. DOI: 10.1111/j.1582-4934.2010.01044.x. View

16.

Serbina N, Pamer E . Monocyte emigration from bone marrow during bacterial infection requires signals mediated by chemokine receptor CCR2. Nat Immunol. 2006; 7(3):311-7. DOI: 10.1038/ni1309. View

17.

Yokosaki Y, Matsuura N, Sasaki T, Murakami I, Schneider H, Higashiyama S . The integrin alpha(9)beta(1) binds to a novel recognition sequence (SVVYGLR) in the thrombin-cleaved amino-terminal fragment of osteopontin. J Biol Chem. 1999; 274(51):36328-34. DOI: 10.1074/jbc.274.51.36328. View

18.

Khakoo A, Pati S, Anderson S, Reid W, Elshal M, Rovira I . Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. J Exp Med. 2006; 203(5):1235-47. PMC: 2121206. DOI: 10.1084/jem.20051921. View

19.

Shinagawa K, Kitadai Y, Tanaka M, Sumida T, Kodama M, Higashi Y . Mesenchymal stem cells enhance growth and metastasis of colon cancer. Int J Cancer. 2010; 127(10):2323-33. DOI: 10.1002/ijc.25440. View

20.

Loebinger M, Kyrtatos P, Turmaine M, Price A, Pankhurst Q, Lythgoe M . Magnetic resonance imaging of mesenchymal stem cells homing to pulmonary metastases using biocompatible magnetic nanoparticles. Cancer Res. 2009; 69(23):8862-7. PMC: 2833408. DOI: 10.1158/0008-5472.CAN-09-1912. View